Home

Check out the latest video from the InSilc project that describes the InSilc Platform and activities.

 

The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), through building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, towards simulating their implantation performance in the individual cardiovascular physiology.

The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for mechanical behaviour, deployment and degradation, fluid dynamics, in the micro– and macroscale, and myocardial perfusion for predicting the drug-eluting BVS and vascular wall interaction, in the short– and medium/long term.

 

New-fig

 

 

Recent Posts

ASME V&V Workshop – April 7th 2021

by researchuniversitygalway

ASME V&V 40 Virtual Workshop Assessing Credibility of Computational Modeling and Simulation Results through Verification and Validation: Application to Medical Devices. April 7, 20211:00 PM-5:30 PM ASME V&V 40 — Assessing Credibility of Computational Modeling and Simulation Results through Verification and Validation: Application to Medical Devices, was published in 2018 to support the credible use … Continue reading ASME V&V Workshop – April 7th 2021

WHAT ARE IN-SILICO CLINICAL TRIALS?

by researchuniversitygalway

An In Silico Clinical Trial is the use of individualised computer simulation in the design, development and regulatory evaluation of a medicinal product, medical device, or medical intervention. Currently. Biomedical product development and assessment is almost completely founded on experimental testing throughout all phases of development chain, from in vitro bench testing, to pre-clinical animal … Continue reading WHAT ARE IN-SILICO CLINICAL TRIALS?

More Posts